Zentalis Pharmaceuticals, Inc.
ZNTL • NASDAQ
Zentalis Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Julie Eastland, with a market cap of $149.0M.
CEOJulie Eastland
Next Earnings
Upcoming earnings announcement for Zentalis Pharmaceuticals, Inc.
Date
Wednesday, May 13, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.48
Earnings History
Past 12 earnings reports for Zentalis Pharmaceuticals, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 2026 | Q4 2025 | -$0.49Est: -$0.53 | +7.5% | - | — |  10-K |
| Nov 10, 2025 | Q3 2025 | -$0.37Est: -$0.48 | +22.9% | - | — | 10-Q |
| Aug 6, 2025 | Q2 2025 | -$0.37Est: -$0.54 | +31.5% | - | — | 10-Q |
| May 14, 2025 | Q1 2025 | -$0.67Est: -$0.61 | -9.8% | - | — | 10-Q |
| Mar 26, 2025 | Q4 2024 | -$0.66Est: -$0.78 | +15.4% | $26.9M | — | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.56Est: -$0.91 | +38.5% | - | — | 10-Q |
| Aug 9, 2024 | Q2 2024 | -$1.24Est: -$0.84 | -47.6% | - | — | 10-Q |
| May 7, 2024 | Q1 2024 | $0.14Est: -$0.77 | +118.2% | $40.6MEst: $13.1M | +209.1% | 10-Q |
| Feb 27, 2024 | Q4 2023 | -$0.83Est: -$0.92 | +9.8% | - | — | 10-K |
| Nov 6, 2023 | Q3 2023 | -$0.79Est: -$0.91 | +13.2% | - | — | — |
| Aug 9, 2023 | Q2 2023 | -$1.85Est: -$1.04 | -77.9% | - | — | 10-Q |
| May 10, 2023 | Q1 2023 | -$1.07Est: -$1.02 | -4.9% | - | — | — |